Gene correction and overexpression of TNNI3 improve impaired relaxation in engineered heart tissue model of pediatric restrictive cardiomyopathy
Development, Growth & Differentiation · 2024
DOI: 10.1111/dgd.12909 ↗At a glance
Journal article in Development, Growth & Differentiation, 2024. Written by Moyu Hasegawa and 13 co-authors. Institution: Department of Cardiovascular Surgery, Osaka University Graduate School of Medicine, Osaka, Japan. Major MEDLINE topics: Cardiomyopathies, Cardiomyopathy, Restrictive, Induced Pluripotent Stem Cells. Cited 7 times so far (Crossref); 48 references. The full text is freely available (open access, CC BY 4.0). Funded by: Japan Society for the Promotion of Science, Japan Agency for Medical Research and Development.
Abstract (original language)
Research on cardiomyopathy models using engineered heart tissue (EHT) created from disease‐specific induced pluripotent stem cells (iPSCs) is advancing rapidly. However, the study of restrictive cardiomyopathy (RCM), a rare and intractable cardiomyopathy, remains at the experimental stage because there is currently no established method to replicate the hallmark phenotype of RCM, particularly diastolic dysfunction, in vitro. In this study, we generated iPSCs from a patient with early childhood‐onset RCM harboring the TNNI3 R170W mutation (R170W‐iPSCs). The properties of R170W‐iPSC‐derived cardiomyocytes (CMs) and EHTs were evaluated and compared with an isogenic iPSC line in which the mutation was corrected. Our results indicated altered calcium kinetics in R170W‐iPSC‐CMs, including prolonged tau, and an increased ratio of relaxation force to contractile force in R170W‐EHTs. These properties were reversed in the isogenic line, suggesting that our model recapitulates impaired relaxation of RCM, i.e., diastolic dysfunction in clinical practice. Furthermore, overexpression of wild‐type TNNI3 in R170W‐iPSC‐CMs and ‐EHTs effectively rescued impaired relaxation. These results highlight the potential efficacy of EHT, a modality that can accurately recapitulate diastolic dysfunction in vitro, to elucidate the pathophysiology of RCM, as well as the possible benefits of gene therapies for patients with RCM.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Department of Cardiovascular Surgery, Osaka University Graduate School of Medicine, Osaka, Japan.
- Premium Research Institute for Human Metaverse Medicine, Osaka University, Osaka, Japan.
- NTT Communication Science Laboratories, Media Information Research Department, Kanagawa, Japan.
- Department of Pediatrics, Osaka University Graduate School of Medicine, Osaka, Japan.
- Department of Medical Therapeutics for Heart Failure, Osaka University Graduate School of Medicine, Osaka, Japan.
- Department of Cardiovascular Medicine, Osaka University Graduate School of Medicine, Osaka, Japan.
ORCID profiles: Moyu Hasegawa, Kenji Miki
Funding
- Japan Society for the Promotion of Science
- Japan Agency for Medical Research and Development
Cite
APA
Hasegawa, M., Miki, K., Kawamura, T., Takei Sasozaki, I., Higashiyama, Y., Tsuchida, M., Kashino, K., Taira, M., Ito, E., Takeda, M., Ishida, H., Higo, S., Sakata, Y., & Miyagawa, S. (2024). Gene correction and overexpression of TNNI3 improve impaired relaxation in engineered heart tissue model of pediatric restrictive cardiomyopathy. Development, Growth & Differentiation. https://doi.org/10.1111/dgd.12909
Vancouver
Hasegawa M, Miki K, Kawamura T, Takei Sasozaki I, Higashiyama Y, Tsuchida M, et al. Gene correction and overexpression of TNNI3 improve impaired relaxation in engineered heart tissue model of pediatric restrictive cardiomyopathy. Development, Growth & Differentiation. 2024. doi:10.1111/dgd.12909
BibTeX
@article{Hasegawa2024,
author = {Hasegawa, Moyu and Miki, Kenji and Kawamura, Takuji and Takei Sasozaki, Ikue and Higashiyama, Yuki and Tsuchida, Masaru and Kashino, Kunio and Taira, Masaki and Ito, Emiko and Takeda, Maki and Ishida, Hidekazu and Higo, Shuichiro and Sakata, Yasushi and Miyagawa, Shigeru},
title = {Gene correction and overexpression of TNNI3 improve impaired relaxation in engineered heart tissue model of pediatric restrictive cardiomyopathy},
journal = {Development, Growth & Differentiation},
year = {2024},
doi = {10.1111/dgd.12909}
}
EUVIMED